Journal article

Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

Jonathan A Ledermann, Christian Marth, Mark S Carey, Michael Birrer, David DL Bowtell, Stan Kaye, Iain McNeish, Amit Oza, Giovanni Scambia, Gordon Rustin, Frederick B Stehman, David Gershenson, Gillian Thomas, Els Berns, Antonio Casado, Nelleke Ottevanger, Felix Hilpert, Byoung-Gie Kim, Aikou Okamoto, Monica Bacon Show all

International Journal of Gynecological Cancer | BMJ PUBLISHING GROUP | Published : 2011

Abstract

There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, cou..

View full abstract

Grants

Awarded by Medical Research Council


Funding Acknowledgements

The 4th Ovarian Cancer Consensus Conference was convened by the GCIG in Vancouver, BC, Canada from June 24th-28th, 2010. Unrestricted grants were gratefully received for support of this conference from Astra Zeneca, Roche, GlaxoSmithKline, Pharmamar, Ortho Biotech, Boehringer Ingelheim, Canadian Cancer Society Research Institute, Ovarian Cancer Canada, National Cancer Institute (US), Taiho, Merck, Pfizer, and Amgen. The agenda, deliberations and final statements were developed entirely by the GCIG with no involvement from the funding sources.